Pharmacovigilance Market Size, Emerging Opportunities, Growth Trends, and Forecast 2034

The Pharmacovigilance market share in 2026 involves collecting and analyzing safety information to evaluate the risks associated with pharmaceutical products. These activities help manufacturers and healthcare organizations monitor adverse drug reactions, maintain safety records, and meet regulatory reporting requirements. Services and software are used throughout clinical development and after products enter the market. The market is evolving as pharmaceutical companies manage larger volumes of safety data and seek more efficient monitoring processes. Specialized providers support case processing, safety reporting, risk assessment, and regulatory compliance. At the same time, automation and artificial intelligence are creating opportunities to improve data analysis and identify potential safety signals more efficiently.

According to Fortune Business Insights, the global pharmacovigilance market size was valued at USD 9.35 billion in 2025 and is projected to grow from USD 10.54 billion in 2026 to USD 31.56 billion by 2034, exhibiting a CAGR of 14.69% during the forecast period. North America dominated the pharmacovigilance market with a share of 40.84% in 2025. Growing drug development activities, increasing adverse drug reaction reporting, and greater adoption of specialized safety services are supporting market expansion.

Market Drivers & Restraints:

Increasing Drug Development and Product Launches

Expanding pharmaceutical research and development activities are generating demand for pharmacovigilance services. New medicines and vaccines require systematic safety monitoring during clinical trials and after commercialization. As product pipelines expand, companies need processes that support adverse event collection, evaluation, and reporting across different markets.

Greater Focus on Patient Safety

Healthcare organizations and pharmaceutical manufacturers are placing greater emphasis on identifying and managing medicine-related risks. Pharmacovigilance helps organizations assess safety information and monitor adverse reactions throughout a product's lifecycle. Greater awareness of adverse drug reaction reporting is supporting investment in dedicated safety teams, service providers, and specialized software.

Artificial Intelligence and Automation

Artificial intelligence is emerging as an important trend in the pharmacovigilance market. AI-powered tools can help analyze large datasets, identify patterns, and support adverse event detection. In April 2023, Parexel International Corporation entered into a collaboration with Partex to use AI-powered solutions to accelerate drug discovery and development. Such initiatives demonstrate the growing interest in technology-enabled pharmaceutical research and safety processes.

Shortage of Skilled Professionals and Funding

Limited funding and a shortage of trained professionals can constrain pharmacovigilance activities. Effective drug safety monitoring requires specialized knowledge, reliable reporting systems, and resources to meet regulatory requirements. These challenges can be particularly significant in markets where dedicated infrastructure and training opportunities remain limited.

Top Companies In The Market

• IQVIA Inc. (U.S.)

• Laboratory Corporation of America Holdings (U.S.)

• Parexel International Corporation (U.S.)

• Accenture (Ireland)

• Cognizant (U.S.)

• Ergomed Group (U.K.)

• Thermo Fisher Scientific Inc. (Pharmaceutical Product Development, LLC) (U.S.)

• ICON plc. (Ireland)

• Quanticate (U.K.)

Market Competitive Landscape:

Competition in the pharmacovigilance market is shaped by service quality, technological capabilities, regulatory expertise, and international reach. Providers are expanding their service portfolios and strengthening partnerships to help pharmaceutical companies manage drug safety responsibilities across clinical and post-marketing stages.

Strategic acquisitions and collaborations are helping companies broaden their geographic presence and technical capabilities. In January 2024, ProPharma Group acquired Clinres Farmacija, a Europe-based clinical trial and pharmacovigilance company, to expand its post-marketing regulatory services and pharmacovigilance presence. These developments reflect the industry's focus on expanding specialist capabilities and serving a wider range of pharmaceutical customers.

Market Segments:

By Type (Service and Software), By Deployment (In-house and Outsource)

By End-User (Contract Research Organizations (CROs), Pharmaceutical & Biotechnology Companies, and Others)

Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/pharmacovigilance-pv-market-102746 

Market Regional Insights:

North America dominated the market in 2025, reaching USD 3.82 billion and accounting for 40.84% of global revenue. The region is projected to reach USD 4.32 billion in 2026. Its established pharmaceutical industry, advanced healthcare infrastructure, and stringent drug safety requirements support demand. The U.S. market is projected to reach USD 3.21 billion in 2026.

Europe generated USD 2.40 billion in 2025, representing 25.64% of the global market, and is projected to reach USD 2.69 billion in 2026. Regulatory requirements, increasing awareness of adverse drug reaction reporting, and the presence of established service providers support regional growth. The U.K. market is projected to reach USD 0.62 billion in 2026, while Germany is expected to reach USD 0.58 billion.

Asia Pacific accounted for USD 1.89 billion in 2025, representing 20.22% of global revenue, and is projected to reach USD 2.15 billion in 2026. Increasing clinical research, new drug and vaccine launches, and expanding healthcare capabilities are supporting demand. Japan is projected to reach USD 0.42 billion, China USD 0.57 billion, and India USD 0.42 billion in 2026.

Future Market Scope:

The pharmacovigilance market is expected to benefit from expanding pharmaceutical research, increasing drug launches, and the continued focus on patient safety. AI-enabled software, automation, and advanced data analysis may improve the efficiency of adverse event processing and safety signal detection. These developments are likely to encourage further investment in technology-enabled monitoring solutions.

Curious About Japan’s Market? Explore the Latest -Pharmacovigilance Market- Insights